Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure
外泌体和细胞外 RNA 生物标志物在心力衰竭中的功能作用和治疗靶向
基本信息
- 批准号:9894484
- 负责人:
- 金额:$ 96.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAreaAutophagocytosisBiological MarkersBiologyCardiacCardiac MyocytesCardiovascular DiseasesCell Culture TechniquesCell physiologyCellsCessation of lifeClinicalComplexDiagnosisDiseaseFibrosisGrantHealth ExpendituresHeart HypertrophyHeart failureHospitalizationHumanInterruptionMeasuresMediatingMentorsModelingMorbidity - disease rateMusMyocardial InfarctionNuclearPathogenesisPatientsPerformancePhenotypePlasmaPlayPrevalenceProcessRNAResearchResearch PersonnelRisk stratificationRoleSamplingSignal PathwaySignal TransductionStructureTimeTissuesUnited StatesWorkbiobankclinical biomarkersclinically actionableexosomeexperimental studyextracellularextracellular vesiclesflexibilityhigh rewardhigh riskimprovedinduced pluripotent stem cellinsightintercellular communicationmortalitymouse modelnew therapeutic targetnext generationnovelnovel therapeuticsorgan on a chipprognosticsmall moleculetherapeutic siRNAtherapeutic targettooltranscriptome sequencinguptakevesicular release
项目摘要
Despite important advances in the treatment of heart failure (HF), >50% of patients die within 5 years of
diagnosis at their first hospital admission, and HF remains a leading cause of morbidity, mortality and
healthcare expenditure in the United States. With the prevalence of HF expected to increase to 46% by 2030,
novel mechanistic insight into HF pathogenesis and strategies to interrupt this progression are a large unmet
clinical need. My research has focused on the role of exosomes or extracellular vesicles (EVs) and their cargo
RNAs (EV-RNAs) as novel functional biomarkers. We have discovered and validated plasma RNA signatures
that correlate with human HF phenotypes such as adverse structural remodeling after myocardial infarction,
fibrosis and sudden arrhythmic death. We have shown that many of these plasma RNAs are sequestered
within EVs and are a novel mode of intercellular communication. Importantly, many of these EV-RNAs change
in parallel in cardiac tissue, modulating complex signaling pathways that may underlie HF pathogenesis. This
work affords a unique opportunity to develop i) novel clinically useful biomarkers for improved risk stratification
of HF patients; and ii) novel therapeutic targets to interrupt the adverse remodeling process.
I now seek to leverage the tools and platforms developed over the past 5 years to move the EV and EV-RNA
field in new directions using the flexible R35 grant mechanism. I seek to broadly address the following broad
areas of unmet need.
1. Improve the performance (including prognostic/predictive accuracy and coefficient of variance) of plasma
RNA biomarkers by more specifically measuring EV-RNAs on validated platforms in biorepository plasma
samples from carefully-phenotyped HF and post-MI patients.
2. Determine a functional role for EVs isolated from human HF samples with varied phenotypes in simplified
cell culture (iPSC-derived CMs) and organ-on-chip models
3. Leverage a novel murine model of exosome tracking (ExoMap) mouse to determine the functional
consequences of exosome targeting in cardiomyocytes and other cardiac cells in murine models of ischemic
and non-ischemic HF using single cell nuclear RNAseq.
4. Identify small molecule regulators of EV release/uptake to manipulate EV-mediated signaling in these
murine models.
5. Leverage newly identified cellular RNA biomarkers to develop novel conditional siRNA therapeutics that
target cardiac hypertrophy, autophagy and fibrosis.
The flexibility and latitude afforded by the R35 mechanism will allow me to pursue these high-risk high-reward
experiments that seek to address critical gaps in this field and will also provide time for devoting to mentoring
of the next generation of cardiovascular disease investigators.
尽管心力衰竭(HF)的治疗取得了重要进展,但仍有>50%的患者在治疗后5年内死亡。
在首次入院时诊断,HF仍然是发病、死亡和死亡的主要原因。
美国的医疗保健支出。预计到2030年,HF的患病率将增加到46%,
对HF发病机制的新的机制见解和中断这种进展的策略是一个很大的未满足的
临床需要我的研究主要集中在外泌体或细胞外囊泡(EV)及其货物的作用
RNA(EV-RNA)作为新的功能性生物标志物。我们已经发现并验证了血浆RNA特征
与人类HF表型相关的疾病,如心肌梗死后的不良结构重塑,
纤维化和猝死。我们已经证明,许多这些血浆RNA被隔离,
在EV内,并且是细胞间通信的新模式。重要的是,这些EV-RNA中的许多都发生了变化,
在心脏组织中平行,调节可能是HF发病机制基础的复杂信号通路。这
工作提供了一个独特的机会,以开发i)新的临床有用的生物标志物,用于改善风险分层
的HF患者;和ii)新的治疗目标,以中断不良重塑过程。
我现在寻求利用过去5年开发的工具和平台,
字段在新的方向使用灵活的R35授权机制。我希望广泛地讨论以下问题
未满足需求的领域。
1.提高血浆的性能(包括预后/预测准确性和变异系数)
通过在生物储存血浆中的经验证平台上更特异性地测量EV-RNA的RNA生物标志物
来自仔细分型的HF和MI后患者的样本。
2.确定从具有不同表型的人HF样本中分离的EV的功能作用,
细胞培养(iPSC衍生的CM)和器官芯片模型
3.利用新型外泌体追踪小鼠模型(ExoMap)来确定功能性
外泌体靶向心肌细胞和其他心肌细胞在缺血性心脏病小鼠模型中的结果
和使用单细胞核RNAseq的非缺血性HF。
4.鉴定EV释放/摄取的小分子调节剂以操纵这些细胞中EV介导的信号传导。
鼠模型。
5.利用新鉴定的细胞RNA生物标志物开发新的条件性siRNA疗法,
靶向心脏肥大、自噬和纤维化。
R35机制所提供的灵活性和自由度将使我能够追求这些高风险高回报的目标。
旨在解决这一领域的关键差距的实验,也将提供时间用于指导
下一代的心血管疾病研究者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Saumya Das其他文献
Saumya Das的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Saumya Das', 18)}}的其他基金
Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease
β细胞特异性细胞外囊泡货物作为 I 型 DM 疾病功能性生物标志物的表征
- 批准号:
10517890 - 财政年份:2022
- 资助金额:
$ 96.07万 - 项目类别:
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk
使用离体、体内模型和患者突变来探究胰腺外分泌-内分泌串扰
- 批准号:
10706558 - 财政年份:2022
- 资助金额:
$ 96.07万 - 项目类别:
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk
使用离体、体内模型和患者突变来探究胰腺外分泌-内分泌串扰
- 批准号:
10594228 - 财政年份:2022
- 资助金额:
$ 96.07万 - 项目类别:
Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease
β细胞特异性细胞外囊泡货物作为 I 型 DM 疾病功能性生物标志物的表征
- 批准号:
10706576 - 财政年份:2022
- 资助金额:
$ 96.07万 - 项目类别:
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure
外泌体和细胞外 RNA 生物标志物在心力衰竭中的功能作用和治疗靶向
- 批准号:
10417068 - 财政年份:2020
- 资助金额:
$ 96.07万 - 项目类别:
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure
外泌体和细胞外 RNA 生物标志物在心力衰竭中的功能作用和治疗靶向
- 批准号:
10176560 - 财政年份:2020
- 资助金额:
$ 96.07万 - 项目类别:
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure
外泌体和细胞外 RNA 生物标志物在心力衰竭中的功能作用和治疗靶向
- 批准号:
10630193 - 财政年份:2020
- 资助金额:
$ 96.07万 - 项目类别:
Molecular dissection and imaging of extracellular vesicles to define their origin and targets
细胞外囊泡的分子解剖和成像以确定其起源和目标
- 批准号:
9811730 - 财政年份:2019
- 资助金额:
$ 96.07万 - 项目类别:
Molecular dissection and imaging of extracellular vesicles to define their origin and targets
细胞外囊泡的分子解剖和成像以确定其起源和目标
- 批准号:
10350010 - 财政年份:2019
- 资助金额:
$ 96.07万 - 项目类别:
Molecular dissection and imaging of extracellular vesicles to define their origin and targets
细胞外囊泡的分子解剖和成像以确定其起源和目标
- 批准号:
10018945 - 财政年份:2019
- 资助金额:
$ 96.07万 - 项目类别:
相似国自然基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
- 批准号:2021JJ40433
- 批准年份:2021
- 资助金额:0.0 万元
- 项目类别:省市级项目
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
- 批准号:32001603
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
AREA国际经济模型的移植.改进和应用
- 批准号:18870435
- 批准年份:1988
- 资助金额:2.0 万元
- 项目类别:面上项目
相似海外基金
Onboarding Rural Area Mathematics and Physical Science Scholars
农村地区数学和物理科学学者的入职
- 批准号:
2322614 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Standard Grant
TRACK-UK: Synthesized Census and Small Area Statistics for Transport and Energy
TRACK-UK:交通和能源综合人口普查和小区域统计
- 批准号:
ES/Z50290X/1 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Research Grant
Wide-area low-cost sustainable ocean temperature and velocity structure extraction using distributed fibre optic sensing within legacy seafloor cables
使用传统海底电缆中的分布式光纤传感进行广域低成本可持续海洋温度和速度结构提取
- 批准号:
NE/Y003365/1 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Research Grant
Point-scanning confocal with area detector
点扫描共焦与区域检测器
- 批准号:
534092360 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Major Research Instrumentation
Collaborative Research: Scalable Manufacturing of Large-Area Thin Films of Metal-Organic Frameworks for Separations Applications
合作研究:用于分离应用的大面积金属有机框架薄膜的可扩展制造
- 批准号:
2326714 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Standard Grant
Collaborative Research: Scalable Manufacturing of Large-Area Thin Films of Metal-Organic Frameworks for Separations Applications
合作研究:用于分离应用的大面积金属有机框架薄膜的可扩展制造
- 批准号:
2326713 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Standard Grant
Unlicensed Low-Power Wide Area Networks for Location-based Services
用于基于位置的服务的免许可低功耗广域网
- 批准号:
24K20765 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
RAPID: Collaborative Research: Multifaceted Data Collection on the Aftermath of the March 26, 2024 Francis Scott Key Bridge Collapse in the DC-Maryland-Virginia Area
RAPID:协作研究:2024 年 3 月 26 日 DC-马里兰-弗吉尼亚地区 Francis Scott Key 大桥倒塌事故后果的多方面数据收集
- 批准号:
2427233 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Standard Grant
RAPID: Collaborative Research: Multifaceted Data Collection on the Aftermath of the March 26, 2024 Francis Scott Key Bridge Collapse in the DC-Maryland-Virginia Area
RAPID:协作研究:2024 年 3 月 26 日 DC-马里兰-弗吉尼亚地区 Francis Scott Key 大桥倒塌事故后果的多方面数据收集
- 批准号:
2427232 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Standard Grant
RAPID: Collaborative Research: Multifaceted Data Collection on the Aftermath of the March 26, 2024 Francis Scott Key Bridge Collapse in the DC-Maryland-Virginia Area
RAPID:协作研究:2024 年 3 月 26 日 DC-马里兰-弗吉尼亚地区 Francis Scott Key 大桥倒塌事故后果的多方面数据收集
- 批准号:
2427231 - 财政年份:2024
- 资助金额:
$ 96.07万 - 项目类别:
Standard Grant